| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 61 | 用于治疗代谢紊乱的化合物 | CN200480010732.3 | 2004-04-20 | CN1777576A | 2006-05-24 | 科尔文·L·霍奇; 罗伯特·J·考夫曼; 阿尔伯特·李; 沙林·夏尔马; 里德·W·冯博斯特尔 |
| 本发明披露了对治疗诸如胰岛素抵抗综合征、糖尿病、高脂血症、脂肪性肝病、恶病质、肥胖症、动脉粥样硬化和动脉硬化等各种代谢紊乱有效的药剂。式I所示的化合物中，n是1或2；m是2或3；q是0或1；t是0或1；R2是具有1至3个碳原子的烷基；R3是氢、卤素、具有1至3个碳原子的烷基或者具有1至3个碳原子的烷氧基；A是苯基，该苯基不具有取代基或被选自以下的1个或2个基团取代：卤素、具有1个或2个碳原子的烷基、全氟甲基、具有1个或2个碳原子的烷氧基和全氟甲氧基；或者A是具有3至6个环碳原子的环烷基，该环烷基不具有取代基或其中的一个或两个环碳独立地被甲基或乙基单取代；或者A是具有选自N、S和O的1或2个环杂原子的5元或6元杂芳环，该杂芳环通过环碳与式I化合物的剩余部分共价键合；并且R1是氢或具有1个或2个碳原子的烷基。或者，当R1是氢时，所述的生物活性剂可以是式I化合物的药学上可接受的盐。 | ||||||
| 62 | 一种高纯度间苯二甲酰氯的制备方法 | CN200410023804.X | 2004-03-17 | CN1229325C | 2005-11-30 | 徐海全; 杨万宏; 杜永顺; 盛丽萍; 马德强 |
| 本发明公开了一种高纯度间苯二甲酰氯的制备方法，该方法是用间苯二甲酸和氯化剂作原料，在催化剂条件下，通过化学反应经分离、精制工艺生产出高纯度间苯二甲酰氯，其纯度可达99.8%以上。 | ||||||
| 63 | 作为用于分离接近沸点或共沸混合物的选择性添加剂的离子液体 | CN02806951.X | 2002-03-14 | CN1524006A | 2004-08-25 | W·阿尔特; M·塞勒; C·乔克; T·施奈德 |
| 本发明涉及一种通过使用离子液体分离接近沸点的均相和多相共沸混合物的方法。由于离子液体的选择性和不同寻常的性能组合，就成本和能量而论，该方法优于普通萃取精馏。 | ||||||
| 64 | 制备高纯芳香羧酸的改进方法 | CN99813784.7 | 1999-11-22 | CN1138745C | 2004-02-18 | Y·-W·苏; C·-L·林 |
| 一种改进的用不纯固体酸产品生产高纯芳香羧酸的方法；用此方法，即使存在固体团块，也可以在相对较低的温度下将固体酸产品高效地溶于适宜的溶剂中。 | ||||||
| 65 | 生产芳族羧酸的方法 | CN99110733.0 | 1999-07-28 | CN1090170C | 2002-09-04 | 中尾藤正; 上田雅则; 岩田秀昭; 富高正; 梅田道生 |
| 生产精制芳族羧酸的方法，包括用含分子氧的气体，在含脂族羧酸的溶剂中，在催化剂存在下，经液相氧化使烷基芳族化合物氧化为芳族羧酸，它以晶体形式析出形成浆料，然后进行精制处理和在结晶器内重结晶，以及分离重结晶过的酸以获得精制的芳族羧酸，其中搅拌罐作为氧化反应器和/或结晶器使用，其下部装有搅拌器，和在搅拌罐中完成的液相氧化和/或重结晶是以维持浆料中的芳族羧酸晶体平均粒径不超过500μm和浆料中晶体的浓度不超过60%(重量)的方式来控制搅拌器的性能。 | ||||||
| 66 | 芳族羧酸的制备方法 | CN99108695.3 | 1999-06-19 | CN1077876C | 2002-01-16 | 中尾藤正; 岩田秀昭; 富高正; 梅田道生 |
| 通过液相氧化制备芳族羧酸的方法，该方法包括：将电力设备、压缩机和膨胀器的旋转轴连接；将电能供应给电力设备以驱动压缩机；加热由压缩机压缩的含分子氧的气体；将加热的压缩气体通入膨胀器；通过向反应器中提供部分由压缩机压缩的含分子氧的气体启动氧化反应；反应开始后，通过向膨胀器通入氧化废气回收能量，从而切断了电源的电力设备产生电能，和向反应器中逐渐增加含分子氧的压缩气体的供应，同时减少其向膨胀器中的供应。 | ||||||
| 67 | 制备高纯芳香羧酸的改进方法 | CN99813784.7 | 1999-11-22 | CN1328536A | 2001-12-26 | Y·W·苏; C·L·林 |
| 一种改进的用不纯固体酸产品生产高纯芳香羧酸的方法;用此方法,即使存在固体团块,也可以在相对较低的温度下将固体酸产品高效地溶于适宜的溶剂中。 | ||||||
| 68 | 对二甲苯的基于氧气的氧化中水含量的优化 | CN97104904.1 | 1997-03-21 | CN1163882A | 1997-11-05 | A·K·罗比; J·P·金士利 |
| 本发明涉及一种制备芳族羧酸的氧化方法，其中所需的水量被优化。结果，降低的蒸汽摩尔流率和降低的沸点改善了高质量产品的生产效率。 | ||||||
| 69 | A PROCESS FOR PRODUCING AROMATIC DICARBOXYLIC ACIDS | PCT/IN2014/000289 | 2014-04-30 | WO2015166507A1 | 2015-11-05 | UPPARA, Parasu Veera; ADURI, Pavankumar; JAIN, Suresh Shantilal; RATNAPARKHI, Uday |
The present disclosure provides a process for preparing an aromatic dicarboxylic acid, particularly terephthalic acid; said process comprising oxidizing p-xylene with an oxidizing agent in the presence of a carboxylic acid solvent, at least one catalyst and at least one ionic liquid. |
||||||
| 70 | COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS | PCT/US2007/077100 | 2007-08-29 | WO2008027958A3 | 2008-03-06 | LIAO, Jun; TANG, Pingwah; GSCHNEIDNER, David; MAEYER, Jonathan |
The present invention provides delivery agent compounds, compositions containing delivery agent compounds and an active agent and methods for delivering active agents, such as biologically or chemically active agents. |
||||||
| 71 | PROCESS AND APPARATUS FOR MANUFACTURING AROMATIC CARBOXYLIC ACIDS INCLUDING PURE FORMS THEREOF | PCT/US2006/010486 | 2006-03-20 | WO2006102459A1 | 2006-09-28 | BARTOS, Thomas, M.; LEUNG, Linus, K. |
A process and apparatus for manufacture of aromatic carboxylic acids comprises a liquid phase oxidation of aromatic hydrocarbon feed materials and treatment of a high pressure off-gas from the liquid phase oxidation to separate water and reaction solvent and preferentially apportion liquid phase oxidation by-product species between gas and liquid phases resulting from separation. Processes for making pure forms of aromatic carboxylic acid also are included. |
||||||
| 72 | PROCESS AND APPARATUS FOR MANUFACTURING PURE FORMS OF AROMATIC CARBOXYLIC ACIDS | PCT/US2006/010255 | 2006-03-20 | WO2006102336A2 | 2006-09-28 | BARTOS, Thomas, M. |
A process and apparatus for manufacture of aromatic carboxylic acids comprises a liquid phase oxidation of aromatic hydrocarbon feed materials and treatment of a high pressure off-gas from the liquid phase oxidation to separate water and reaction solvent and purification of impure aromatic carboxylic acid products wherein a purification liquid includes water from off- gas treatment. |
||||||
| 73 | PHENYLCARBOXYLATE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | PCT/US2004020525 | 2004-06-25 | WO2005004803A3 | 2005-04-21 | NANTERMET PHILIPPE G; RAJAPAKSE HEMAKA ANTHONY; SELNICK HAROLD G |
| The present invention is directed to compounds which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the beta-secretase enzyme is involved. | ||||||
| 74 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | PCT/US2004012142 | 2004-04-20 | WO2004093806A3 | 2005-04-07 | HODGE KIRVIN L; KAUFMAN ROBERT J; LEE ALBERT; SHARMA SHALINI; VON BORSTEL REID W |
| Agents useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis are disclosed. Formula (I) wherein n is 1 or 2; m is 2 or 3; q is 0 or 1; t is 0 or 1; R<2> is alkyl having from 1 to 3 carbon atoms; R<3> is hydrogen, halo, alkyl having from 1 to 3 carbon atoms, or alkoxy having from 1 to 3 carbon atoms; A is phenyl, unsubstituted or substituted by 1 or 2 groups selected from: halo, alkyl having 1 or 2 carbon atoms, perfluoromethyl, alkoxy having 1 or 2 carbon atoms, and perfluoromethoxy; or cycloalkyl having from 3 to 6 ring carbon atoms wherein the cycloalkyl is unsubstituted or one or two ring carbons are independently mono-substituted by methyl or ethyl; or a 5 or 6 membered heteroaromatic ring having 1 or 2 ring heteroatoms selected from N, S and O and the heteroaromatic ring is covalently bound to the remainder of the compound of formula I by a ring carbon; and R<1> is hydrogen or alkyl having 1 or 2 carbon atoms. Alternatively, when R<1> is hydrogen, the biologically active agent can be a pharmaceutically acceptable salt of the compound of Formula (I). | ||||||
| 75 | IONIC LIQUIDS AS SELECTIVE ADDITIVES FOR THE SEPARATION OF CLOSE-BOILING OR AZEOTROPIC MIXTURES | PCT/EP0202824 | 2002-03-14 | WO02074718A3 | 2002-11-28 | ARLT WOLFGANG; SEILER MATTHIAS; JORK CARSTEN; SCHNEIDER THOMAS |
| The invention relates to a method for separating close-boiling homo and heteroazeotropic mixtures using ionic liquids. The method is superior to conventional extractive rectification in terms of cost-effectiveness and exergetic aspects as a result of the selectivity and the unusual characteristic profile of the ionic liquids. | ||||||
| 76 | FATTY ACID SYNTHASE INHIBITORS | PCT/US2001/024460 | 2001-08-02 | WO02009688A1 | 2002-02-07 | |
| This invention relates to the use of compounds as inhibitors of the fattty acid synthase FabH. | ||||||
| 77 | METHOD OF PRODUCING AROMATIC CARBOXYLIC ACIDS | PCT/KR1999/000783 | 1999-12-17 | WO00037406A1 | 2000-06-29 | |
| An improved production method of aromatic carboxylic acids of significantly improved yields and quality by oxidizing alkyl aromatic substrates or their partially oxidized intermediates by oxygen-enriched gas in a conventional Co-Mn-Br catalyst system containing additional components such as a transition metal or lanthanide metal component in an aliphatic carboxylic acid having 1 SIMILAR 6 carbon atoms. In other words, a decline in reactivity in the later part of the oxidation reaction and the precipitation of a catalyst such as manganese were effectively deterred by means of incorporating one or more than one type of transition or lanthanide metal components selected from such metals as Ce, Zr, Hf, Fe, Cr, and Mo during the oxidation reaction with oxygen-enriched gas. With this invention, pure aromatic carboxylic acids with white color can be obtained with high selectivity and reactivity by oxidation of substrates with oxygen-enriched gas. The oxidation reaction of alkylaromatic substrates proceeds more selectively with a much faster rate to produce aromatic carboxylic acids of improved quality as compared to those of conventional oxidation processes. | ||||||
| 78 | HYDROFORMYLATION WITH UNMODIFIED RHODIUM CATALYSTS IN SUPERCRITICAL CARBON DIOXIDE | PCT/EP1998/004319 | 1998-07-11 | WO99003810A1 | 1999-01-28 | |
| The invention relates to a method for producing oxo products by hydroformylation of substrates with C=C double bonds, using unmodified rhodium catalysts in a reaction mixture consisting essentially of the substrates, the catalyst and carbon dioxide in a supercritical state (scCO2). The invention especially relates to methods of this kind for producing products containing substantial parts of branched i-oxo products. The invention further relates to methods of this kind for the hydroformylation of substrates not corresponding to the general formula C2H2n. The invention also relates to said methods in which the product and catalyst are separated using the special solubilizing properties of scCO2. | ||||||
| 79 | ALKYNE COMPOUNDS AS S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS | PCT/IB2015/057661 | 2015-10-07 | WO2016055947A1 | 2016-04-14 | GHARAT, Laxmikant Atmaram; MUTHUKAMAN, Nagarajan; PISAL, Dnyandeo; KHAIRATKAR-JOSHI, Neelima; SHAH, Daisy Manish; KADAM, Sheetal R |
Provided are compounds of formula (Ia) and pharmaceutically acceptable salts thereof, wherein A, B, R 1, R 2, m and n are as defined herein, which are active as inhibitors of S-Nitrosoglutathione reductase (GSNOR). These compounds prevent, inhibit, or suppress the action of GSNOR and are therefore useful in the treatment of GSNOR mediated diseases, disorders, syndromes or conditions such as, e.g., pulmonary hypertension, acute respiratory distress syndrome (ARDS), asthma, bronchospasm, cough, pneumonia, pulmonary fibrosis, interstitial lung diseases, cystic fibrosis and chronic obstructive pulmonary disease (COPD). |
||||||
| 80 | VERFAHREN ZUR HERSTELLUNG FREIER SÄUREN AUS IHREN SALZEN | PCT/EP2010/051170 | 2010-02-01 | WO2010094554A1 | 2010-08-26 | SCHRAVEN, Alexander; TACKE, Thomas; HAAS, Thomas; KOBLER, Christoph; BUSS, Dieter; RONNEBURG, Axel; ZEHNACKER, Olivier |
Die hier beschriebene Erfindung umfasst ein verbessertes Verfahren zur Freisetzung einer organischen Säure, bevorzugt einer Carbon-, Sulfon- oder Phosphonsäure, speziell einer alpha- oder beta-Hydroxycarbonsäure, aus deren Ammoniumsalz durch Freisetzen und Entfernen von Ammoniak und gleichzeitiger Extraktion der freiwerdenden Säure mit einem Amin als geeignetem Extraktionsmittel aus der wässrigen Phase. Dieses Verfahren entspricht einer Reaktivextraktion. Die Reaktivextraktion einer organischen Säuren aus deren wässrigen Ammoniumsalzlösung kann durch den Einsatz eines Strippmediums bzw. Schleppgases wie z.B. Stickstoff, Luft, Wasserdampf oder Inertgase wie z.B. Argon deutlich verbessert werden. Der freigesetzte Ammoniak wird durch den kontinuierlichen Gasstrom aus der wässrigen Lösung entfernt und kann erneut in einen Produktionsprozess eingespeist werden. Die freie Säure kann durch ein Verfahren wie Destillation, Rektifikation, Kristallisation, Rückextraktion, Chromatographie, Adsorption oder durch ein Membranverfahren aus dem Extraktionsmittel gewonnen werden. |
||||||
